arrow
C

Chiara Mercinelli

vita-salute san raffaele university
H指数:10
被引数:295

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

新辅助尼沃鲁单抗联合或不联合维苏格罗单抗治疗肌层浸润性膀胱癌:GDFATHER-NEO 2a期试验

2026-10-240
OAAI
Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials

辅助性帕博利珠单抗联合belzutifan与安慰剂在透明细胞肾细胞癌中的比较:KEYNOTE-564和LITESPARK-022试验的重建生存数据分析

2026-09-110
OAAI
PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

PROTEUS试验次日:改变实践还是过早升级?

2026-09-010
PRE
TOWARDS GENDER EQUITY IN RENAL SURGERY: UNDERSTANDING SEX-BASED DIFFERENCES IN PERIOPERATIVE OUTCOMES

迈向肾脏手术中的性别平等:理解围手术期结果的性别差异

2026-05-010
PRE
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study

免疫检查点抑制剂再挑战在转移性透明细胞肾细胞癌中的结局:全球真实世界证据研究的结果

2026-04-210
OAAI
Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy

同源重组缺陷和基因组改变在晚期前列腺癌中的研究:精准治疗的启示

2026-04-010
PRE
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)

Avelumab维持治疗在晚期尿路上皮癌中的真实世界有效性:来自意大利多中心MALVA研究(Meet-URO 25)的结果

2025-12-010
PRE
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis

基于疾病体积的转移性激素敏感型前列腺癌最佳治疗方法: 系统评价和网络荟萃分析

2025-11-170
OA
Impact of timing between neoadjuvant therapy and radical cystectomy on survival in muscle-invasive bladder cancer

新辅助治疗与根治性膀胱切除术时间间隔对肌层浸润性膀胱癌预后的影响

2025-11-080
PRE
Impact of Body Mass Index on Renal Function Impairment in Patients Treated for Renal Cell Carcinoma at High Risk of Recurrence: Key Implications for Systemic Therapy Eligibility

体重指数对复发高风险肾细胞癌治疗患者肾功能损害的影响:对系统性治疗资格的关键启示

2025-11-010
PRE
T-cell Engagers in Prostate Cancer

T细胞结合剂在前列腺癌中的应用

2025-05-011
PRE
Neoadjuvant sacituzumab govitecan, followed by radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC): Updated interim results of SURE-01 trial

新辅助沙西妥珠单抗戈维他奈,随后进行根治性膀胱切除术,用于肌肉浸润性膀胱癌(MIBC)患者:SURE-01试验的更新中期结果

2024-12-010
PRE
NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring

NETOS:一种针对肌肉浸润性尿路上皮膀胱癌(MIBC)的新辅助治疗个性化方案,包括INCB099280单药治疗和膀胱保留,并伴有循环肿瘤DNA(ctDNA)监测

2024-09-010
PRE
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer

新辅助派姆单抗与以顺铂为基础的化疗或前期根治性膀胱切除术在肌层浸润性尿路上皮膀胱癌患者中的疗效比较

2024-06-015
PRE